US5346897A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
Assignee: SmithKline Beecham Corp
•
Filing: 1992-06-10
•
Granted: 1994-09-13
•
Expires: 2012-06-10
Abstract
Abstract Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are acrivastine esters and the pharmaceutically acceptable salts thereof.
Inventors
- 👤 Ann C. King
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 14:52
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/06; C07D295/073; A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/395; A61K31/40; A61K31/435; A61K31/44; A61K31/495; A61K31/55; C07D213/00; C07D213/02; C07D213/04; C07D213/24; C07D213/54; C07D213/55; C07D213/56; C07D295/08; C07D295/096; C07D295/14; C07D295/155; C07D313/00; C07D313/02; C07D313/06; C07D313/10; C07D313/12
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
84 words
A method of increasing the sensitivity of a tumor to an antineoplastic agent, which tumor is harbored in a subject and which tumor is resistant to said antineoplastic agent, comprising concurrently administering to said subject an antineoplastic agent and a potentiating agent, said potentiating agent selected from the class consisting of ##STR2## wherein R is C 1-4 alkyl, and the pharmaceutically acceptable salts thereof, said potentiating agent being administered in an amount effective to increase the sensitivity of said tumor to said antineoplastic agent.
Claim 2
Independent Claim
84 words
A method of increasing the sensitivity of a tumor to an antineoplastic agent, which tumor is harbored in a subject and which tumor is resistant to said antineoplastic agent, comprising concurrently administering to said subject an antineoplastic agent and a potentiating agent, said potentiating agent selected from the class consisting of ##STR2## wherein R is C 1-4 alkyl, and the pharmaceutically acceptable salts thereof, said potentiating agent being administered in an amount effective to increase the sensitivity of said tumor to said antineoplastic agent.
Claim 3
Dependent Claim
26 words
A method according to claim 1, wherein said antineoplastic agent is administered to said subject parenterally and said potentiating agent is administered to said subject parenterally.
Claim 4
Dependent Claim
36 words
A method according to claim 1, wherein said antineoplastic agent is selected from the class consisting of vinca alkaloids, epipodophyllotoxins, anthracycline antibiotics, actinomycin D, plicamycin, puromycin, gramicidin D, taxol, colchicine, cytochalasin B, emetine, maytansine, and amsacrine.
Claim 5
Dependent Claim
12 words
A method according to claim 1, wherein said tumor is an adenocarcinoma.
Claim 6
Dependent Claim
10 words
A method according to claim 1, wherein R is ethyl.
Claim 7
Dependent Claim
54 words
A pharmaceutical formulation comprising, in a pharmaceutically acceptable carrier, a tumor-inhibiting amount of an antineoplastic agent and a potentiating agent in an amount effective to enhance the efficacy of said antineoplastic agent, said potentiating agent selected from the class consisting of ##STR3## wherein R is C 1-4 alkyl, and the pharmaceutically acceptable salts thereof.
Claim 8
Dependent Claim
54 words
A pharmaceutical formulation comprising, in a pharmaceutically acceptable carrier, a tumor-inhibiting amount of an antineoplastic agent and a potentiating agent in an amount effective to enhance the efficacy of said antineoplastic agent, said potentiating agent selected from the class consisting of ##STR3## wherein R is C 1-4 alkyl, and the pharmaceutically acceptable salts thereof.
Claim 9
Dependent Claim
38 words
A pharmaceutical formulation as claimed in claim 6, wherein said antineoplastic agent is selected from the class consisting of vinca alkaloids, epipodophyllotoxins, anthracycline antibiotics, actinomycin D, plicamycin, puromycin, gramicidin D, taxol, colchicine, cytochalasin B, emetine, maytansine, and amsacrine.
Claim 10
Dependent Claim
12 words
A pharmaceutical formulation as claimed in claim 7, wherein R is ethyl.
References Cited (Backward Citations)
CH419172A
Cited
DE1493451A1
Cited
CH407990A
Cited
GB1018985A
Cited
FR4016M
Cited
US3497596A
Cited
DE1909408A1
Cited
US3996222A
Cited
US3993757A
Cited
EP0013335A1
Cited
US4650807A
Cited
US4657918A
Cited
US4562258A
Cited
EP0085959A2
Cited
GB2120941A
Cited
US4628047A
Cited
DE3410848A1
Cited
EP0135087A1
Cited
US4757074A
Cited
US4690933A
Cited
JPS6185320A
Cited
EP0187700A1
Cited
EP0214779A1
Cited
EP0351887A1
Cited
EP0270926A2
Cited
EP0353692A2
Cited
EP0361485A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-09-12 | 1998-03-14 | 1998-09-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-09-12 | 2002-03-14 | 2002-09-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-09-12 | 2006-03-14 | 2006-09-13 | $7700.00 | Window Closed / Lapsed |